Bio-Medical Technology Company
Specializing in Therapeutic Ultrasound

We will introduce to the world
innovative solutions for enhancing human health,
based on the unprecedented application of
cutting-edge ultrasound technology

About us

We are experts in therapeutic ultrasound technology.
We develop innovative therapeutic ultrasound devices to improve
the lives of numerous patients with severe diseases and disorders.
In particular, our Sono DDS technology will change the entire pharmaceutical
value chain. Sono DDS will enable pharmaceutical companies to produce safer,
easier and better drugs, ultimately contributing to saving and improving
the lives of suffering patients.

Technology

Sono DDS Platform
By utilizing Focused Ultrasound technology which turns drugs with high rate of PPB at specific regions into free(unbound) form, we enhance the local delivery of the drug.
Benefits:
Sono DDS can

lower toxicity and side effects in the system.
* Excessive drugs in the system leads to toxicity
reduce the dosage of medicine, thereby minimizing the drug's toxicity and side effects.
increase the efficacy and safety of the drug at the target position.

News

  • 2020.09.14

    • 한림제약(주)과 Sono DDS 관련 약물 공동연구 협약체결
  • 2020.07.30

    • Certificate of Venture Business – Certificate No: 20200110075
  • 2020.07.17

    • Patent Filing (KR) - Application Number: 10-2020-0088695
    • Title: 뇌 림프계의 노폐물 배출 촉진을 위한 초음파장치
  • 2020.07.16

    • Patent Filing (US) - Application Number: 16930643
    • Title: Ultrasound Device for Facilitating Waste Clearance of the Brain Lymphatic System
  • 2020.06.05

    • Patent Filing - International Application Number: PCT/US20/36335
    • Title: System and Method for Unbinding of Plasma Protein-Bound Active Agents Using an Ultrasound System
  • 2020.05.11

    • Thesis Publication: UMB(Ultrasound in Medicine & Biology)
    • InPress_Xu et al. 2020 - Localized disruption of blood albumin–phenytoin binding using transcranial
  • 2019.11.21

    • Conclusion of SRA (Sponsored Research Agreement) with 'Brigham and Women's Hospital'
  • 2019.10.31

    • Conclusion of Exclusive Option Agreement with 'Brigham and Women's Hospital'
  • 2019.06.06

    • Provisional Patent Filing: BWH25324
    • Title: System and Method for Unbinding of Plasma Protein-Bound Active Agents Using an Ultrasound System
  • 2018.09.11

    • Conclusion of CDA (Confidentiality Disclosure Agreement)
    • with 'Brigham and Women's Hospital' at Harvard Medical School

Contact us

HEAD OFFICE
Seoul National University Bundang Hospital Healthcare
Innovation Park 6F, 172, Dolma-ro, Bundang-gu, Seongnam-si,
Gyeonggi-do, South Korea
☎ 031-713-5450
R&D CENTER
Seoul National University Bundang Hospital Healthcare
Innovation Park 6F, 172, Dolma-ro, Bundang-gu, Seongnam-si,
Gyeonggi-do, South Korea
☎ 070-7722-2660

© DEEPSONBIO